This out-of-favor drug maker is taking the steps needed to ensure it not only survives but thrives over the long term.

It expects to shift from a major investment phase to returning more cash to investors. Enterprise Products Partners recently ...

Real estate stocks were the third-best sector this year but not all REITs produced returns. To make money on your real estate ...

There’s plenty of reason to remain bullish on Novo Nordisk. Even with the challenges it has faced recently, the company ...

In the current era of ASX 200 banks and mining shares not paying as much in dividend income, investors might consider ETFs ...

Western Asset Global High Income Fund offers a 13.1% yield and global diversification. Read why I maintain Hold rating on EHI ...

Canadian Imperial Bank of Commerce looks overpriced, which makes it hard for newcomers to go long at this level. Read why CM stock is not a sell despite this.

Singapore investor interest in US tech stocks surges, with Meta, Amazon, and Microsoft leading activity after Q3 results.

Ajanta Pharma Ltd., a small-cap pharmaceutical company, reported steady growth in its financial performance for the quarter and half-year ended 30 September 2025. The company’s Board of Directors ...

Record free cash flow of approximately $700 million and achieved net cash position Increased 2025 share buyback target by 20% to $600 million and ...

Pfizer (PFE), one of the world’s oldest and most respected pharmaceutical companies, is currently facing significant stock ...